ESR1 and breast cancer: Triple-negative breast cancer (TNBC) represents the most aggressive breast cancer subtype and is characterized by the absence of estrogen receptor, progesterone receptor, and HER2 expression; this subtype affects approximately 12–20% of all breast cancer cases, with a disproportionately poor prognosis and limited therapeutic options.